APA

Drews A., Bovens S., Roebrock K., Sunderkötter C., Reinhardt D., Schäfers M., van der Velde A., Schulze Elfringhoff A., Fabian J. & Lehr M. (20100825). 1-(5-carboxyindol-1-yl)propan-2-one inhibitors of human cytosolic phospholipase A(2)alpha with reduced lipophilicity: synthesis, biological activity, metabolic stability, solubility, bioavailability, and topical in vivo activity. : Journal of medicinal chemistry.

Chicago

Drews Andreas, Bovens Stefanie, Roebrock Kirsten, Sunderkötter Cord, Reinhardt Dirk, Schäfers Michael, van der Velde Andrea, Schulze Elfringhoff Alwine, Fabian Jörg and Lehr Matthias. 20100825. 1-(5-carboxyindol-1-yl)propan-2-one inhibitors of human cytosolic phospholipase A(2)alpha with reduced lipophilicity: synthesis, biological activity, metabolic stability, solubility, bioavailability, and topical in vivo activity. : Journal of medicinal chemistry.

Harvard

Drews A., Bovens S., Roebrock K., Sunderkötter C., Reinhardt D., Schäfers M., van der Velde A., Schulze Elfringhoff A., Fabian J. and Lehr M. (20100825). 1-(5-carboxyindol-1-yl)propan-2-one inhibitors of human cytosolic phospholipase A(2)alpha with reduced lipophilicity: synthesis, biological activity, metabolic stability, solubility, bioavailability, and topical in vivo activity. : Journal of medicinal chemistry.

MLA

Drews Andreas, Bovens Stefanie, Roebrock Kirsten, Sunderkötter Cord, Reinhardt Dirk, Schäfers Michael, van der Velde Andrea, Schulze Elfringhoff Alwine, Fabian Jörg and Lehr Matthias. 1-(5-carboxyindol-1-yl)propan-2-one inhibitors of human cytosolic phospholipase A(2)alpha with reduced lipophilicity: synthesis, biological activity, metabolic stability, solubility, bioavailability, and topical in vivo activity. : Journal of medicinal chemistry. 20100825.